Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment
Aurinia Pharmaceuticals' LUPKYNIS, an FDA-approved treatment for lupus nephritis, is well-positioned to become a new standard of care due to its dual role in immunosuppression and kidney protection. The partnership with Otsuka Pharmaceutical supports Aurinia's international expansion into European and Asian markets. AUR200, now in Phase 1 trials, could be a significant future value driver targeting autoimmune diseases.
Aurinia Pharmaceuticals: This Recovery Can Continue
Aurinia Pharmaceuticals shows promising growth with increased Lupkynis sales. The near future could see a $10M milestone for Japanese approval and royalty payments from Japanese sales. AUPH is developing AUR200, with a phase 1 trial underway allowing it to diversify beyond Lupkynis. The Company reported a $722K net income for Q2'24, up from a $10.7M net loss in Q1'24.
Aurinia Pharmaceuticals, Inc. (AUPH) Q2 2024 Earnings Call Transcript
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - Chief Medical Officer Joe Miller - CFO Conference Call Participants Joseph Schwartz - Leerink Partners Stacy Ku - TD Cowen Ed Arce - H.C. Wainwright & Co. Operator Good day, ladies and gentlemen.
Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.08 per share a year ago.
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Aurinia Pharmaceuticals Appears Undervalued
Aurinia Pharmaceuticals stock has dropped more than 80% due to disappointing Lupkynis sales since its launch in 2021. Management is focusing solely on driving Lupkynis sales and cutting costs by laying off 25% of its sales force and discontinuing other programs. With positive cash flow expected soon, a $150 million share repurchase plan, and strong financials, Aurinia is undervalued and worth considering for investment.
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
3 Biotech Names Under $10 I Own
Today, we take a look at three promising biotech names that currently trade under $10 a share. Two of these are quickly moving towards profitability, and the other is cash rich and has several partnerships with large pharma companies. We profile all three of these names with favorable risk/reward profiles in the paragraphs below.
